mRNA COVID-19 Vaccines Appear Preferable for Patients With I
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Almost everyone with inflammatory bowel disease (IBD) who received one of the three COVID-19 vaccines authorized for emergency use in the United States developed antibodies, researchers found. But antibody titers were significantly higher among those who had received both doses of the Pfizer/BioNTech or Moderna mRNA vaccines compared with the one-dose adenovirus-vector vaccine from Johnson & Johnson, according to a report.

Among the 353 vaccine recipients with IBD and no prior COVID-19 infection, 148 (42%), 193 (55%), and 12 (3%) had been fully vaccinated with the Moderna, Pfizer, and Johnson & Johnson vaccines, respectively. Demographic and disease characteristics were similar across vaccine groups (mean age 51 years, 62% female). Roughly 83% were taking biologics, Janus kinase-inhibitors, systemic corticosteroids, other immunomodulators, or some combination.

Antibody levels were measured at least two weeks and eight weeks after the final vaccine dose. At two weeks, positive antibody levels were detected in 121 (100%), 142 (99%), and 9 (90%) patients in the Moderna, Pfizer, and Johnson & Johnson groups, respectively. At both two and eight weeks, however, antibody titers were significantly higher in the mRNA groups. At the later point, for example, quantitative log10 (anti-Spike IgG) levels were 3.72 in the Moderna group, 3.41 in the Pfizer group, and 2.65 in the Johnson & Johnson group.

On multivariate analysis, at weeks two and eight the vaccine type was independently associated with antibody levels, the researchers said. At week eight, lower titers were also independently associated both with a longer duration between completion of vaccine regimen and blood sampling, and with receipt of immunomodulatory therapy.

The finding of positive antibody levels "in virtually all IBD vaccine recipients," regardless of vaccine type and background treatment regimen, "is reassuring for patients with IBD, and supports existing literature that the vast majority of IBD patients, regardless of immunomodulatory therapy receipt, achieve positive humoral response to mRNA vaccines," the authors wrote.